Individualized magnetic resonance imaging-based neoadjuvant chemoradiation for middle and lower rectal carcinoma

Colorectal Disease

Volumn 13, Issue 1, 2011, Pages 39-47

  Hermanek, P ^a   Hohenberger, W ^a   Fietkau, R ^a   Rodel C ^b  

^a UNIVERSITY HOSPITAL ERLANGEN   (Germany)

^b UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Circumferential resection margin; Magnetic resonance imaging; Middle and lower rectal carcinoma; Neoadjuvant chemoradiation; Quality assurance

Indexed keywords

FLUOROURACIL; MITOMYCIN C;

ARTICLE; CANCER ADJUVANT THERAPY; CANCER CLASSIFICATION; CANCER SURGERY; CHEMORADIOTHERAPY; CLINICAL EFFECTIVENESS; HISTOPATHOLOGY; HUMAN; INDIVIDUALIZATION; NUCLEAR MAGNETIC RESONANCE IMAGING; PATIENT DECISION MAKING; PRACTICE GUIDELINE; PREOPERATIVE EVALUATION; PRIORITY JOURNAL; PROGNOSIS; QUALITY CONTROL; RECTUM CARCINOMA; TREATMENT INDICATION; TUMOR LOCALIZATION;

COMBINED MODALITY THERAPY; DECISION MAKING; HUMANS; MAGNETIC RESONANCE IMAGING; NEOADJUVANT THERAPY; NEOPLASM STAGING; PROGNOSIS; RECTAL NEOPLASMS;

EID: 78650485244     PISSN: 14628910     EISSN: 14631318     Source Type: Journal    
DOI: 10.1111/j.1463-1318.2009.02076.x     Document Type: Article

References (89)

1. Glynne-Jones R, Sebag-Montefiore D. Rectal cancer: what can we learn from the TNM study? How will this study impact on current practice in the UK? Clin Oncol 2002; 14: 170-3.
2. Ooi BS, Tjandra JJ, Green MD. Morbidities of adjuvant chemotherapy and radiotherapy for resectable cancer. An overview. Dis Colon Rectum 1999; 42: 403-18.
3. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Occurrence of second cancers in patients treated with radiotherapy for rectal cancer. J Clin Oncol 2005; 23: 6126-31.
4. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late adverse effects of radiation therapy for rectal cancer-a systematic overview. Acta Oncol 2007; 46: 504-16.
5. Heald RJ, Daniels IR. Rectal cancer management. Europe is ahead. Recent Results Cancer Res 2005; 165: 75-81.
6. Pahlman L. Indications for long-term radiotherapy. Recent Results Cancer Res 2005; 165: 212-200.
7. Burton S, Brown G, Daniels I et al. MRI directed multidisciplinary team reoperative treatment strategy: the way to eliminate positive circumferential margins? Br J Cancer 2006; 94: 351-7.
8. Junginger Th, Hermanek P, Oberholzer K, Schmidberger H. Rektumkarzinom: Behandeln wir zu häufig neoadjuvant? Vorschläge zu einer selektiveren, MRT-basierten Indikation. Zentralbl Chir 2006; 131: 275-84.
9. Sebag-Montefiore D. Developments in the use of chemoradiotherapy in rectal cancer. Colorect Dis 2006; 8(Suppl 3): 14-7.
10. Frileux P, Burdy G, Aegerter P et al. Surgical treatment of rectal cancer: results of a strategy for selective preoperative radiotherapy. Gastroenterol Clin Biol 2007; 31: 934-40.
11. Wieder HA, Rosenberg R, Lordick F et al. Rectal cancer: MR imaging before neoadjuvant chemoradiotherapy for prediction on tumor-free circumferential resection margins and long-term survival. Radiology 2007; 243: 744-51.
12. Moser L, Ritz J-P, Hinkelbein W, Höcht S. Adjuvant and neoadjuvant chemoradiation or radiotherapy in rectal cancer - a review focusing on open questions. Int J Colorect Dis 2008; 23: 227-36.
13. Smith N, Brown G. Preoperative staging of rectal cancer. Acta Oncol 2008; 47: 20-31.
14. Fielding LP, Arsenault PA, Chapuis PH et al. Clinicopathological staging for colorectal cancer: an international documentation system (IDS) and an international comprehensive anatomical terminology (ICAT). J Gastroenterol Hepatol 1991; 6: 325-44.
15. Soreide N, Norstein J, Fielding LP, Silen W. (1997) International standardization and documentation of the treatment of rectal cancer. In: Rectal cancer surgery. Optimisation - standardisation - documentatiaon (eds Soreide O, Norstein J), pp. 405-45. Springer, Berlin Heidelberg New York.
16. UICC (eds Wittekind Ch, Greene FL, Henson DE et al. (2003 3rd edition). TNM Supplement. A commentary on uniform use. John Wiley & Sons, New York.
17. UICC (2002 6th edition) In: TNM classification of malignant tumours (eds Sobin LH, Wittekind Ch). John Wiley & Sons, New York.
18. Quirke P, Dixon MP. The prediction of local recurrence in rectal adenocarcinoma by histopathological examination. Int J Colorect Dis 1988; 3: 127-31.
19. Compton C. Colorectal carcinoma. Diagnostic, prognostic and molecular factors. Mod Pathol 2003; 16: 376-85.
20. Wittekind Ch, Compton CC, Greene FL, Sobin LH. TNM residual tumor classification revisited. Cancer 2002; 94: 2511-6.
21. Wittekind Ch, Compton C, Quirke P et al. (2009) A uniform residual tumour classification. Integration of the R classification and the circumferential margin status. Cancer 2009; 115: 3483-8.
22. Nagtegaal ID, Quirke P. What is the role of the circumferential margin in the modern treatment of rectal cancer? J Clin Oncol 2008; 26: 303-12.
23. Strassburg J, Junginger T, Trinh T et al. Magnetic resonance imaging (MRI)-based indication for neoadjuvant treatment of rectal carcinoma and the surrogat endpoint CRM status. Int J Colorect Dis 2008; 23: 1099-107.
24. Merkel S, Mansmann U, Hohenberger W, Hermanek P. Einheitliche Berechnung von Lokalrezidivraten - Voraussetzungen für das Qualitätsmanagement beim Rektumkarzinom. Z ärztl Fortbild Qual Gesundhwes 2006; 100: 183-97.
25. Merkel S, Mansmann U, Hohenberger W, Hermanek P Time to locoregionalrecurrence after curative resection of rectal carcinoma is influenced by neoadjuvant treatment. Implications for follow-up time needed for reliable treatment results statistics. Colorect Dis 2009, in press.
26. Lopez-Kostner F, Lavery IC, Hool GR et al. Total mesorectal excision is not necessary for cancers of the upper rectum. Surgery 1998; 124: 612-8.
27. Arnoletti JP, Bland KI. Neoadjuvant and adjuvant therapy for rectal cancer. Surg Oncol Clin N Am 2006; 15: 147-57.
28. Ceelen W, Pattyn P, Boterberg T, Peeters M. Pre-operative combined modality therapy in the management of locally advanced rectal cancer. Eur J Surg Oncol 2006; 32: 259-68.
29. Junginger T, Hermanek P. Probleme bei der Therapie des oberen Rektumkarzinoms. Chirurg 2008; 79: 327-39.
30. Edwards DP, Mortensen NJMcC. Is radiotherapy for rectal cancer indicated if surgery is optimized? Eur J Surg Oncol 2001; 27: 442-5.
31. Heald RJ, Husband EM, Ryall RD. The mesorectum in rectal cancer surgery - the clue to pelvic recurrence? Br J Surg 1982; 69: 613-6.
32. Hohenberger W, Schick CH, Göhl J. Mesorectal lymph node dissection: it is benefitial? Langenbeck's Arch Surg 1995; 383: 402-8.
33. Havenga K, Enker WE, Norstein J et al. Improved survival and local control after total mesorectal excision or D3 lymphadenectomy in the treatment of primary rectal cancer: an international analysis of 1411 patients. Eur J Surg Oncol 1999; 25: 368-74.
34. Quirke P.. (1997) Limitations of existing systems of staging for rectal cancer: the forgotten margin. In: Rectal cancer surgery. Optimisation - standardisation - documentation (eds Soreide O, Norstein J), pp. 63-81. Springer, Berlin, Heidelberg, New York.
35. Hermanek P, Junginger Th. The circumferential resection margin in rectal carcinoma surgery. Tech Coloproctol 2005; 9: 193-200.
36. Glynne-Jones R, Mawdsley S, Pearce T, Buyse M. Alternative clinical end points in rectal cancer - are we getting closer? Ann Oncol 2006; 17: 1239-42.
37. Wibe A, Rendedal PR, Svensson E et al. Prognostic significance of the circumferential resection margin following total mesorectal excision for rectal cancer. Br J Surg 2002; 89: 327-34.
38. Hermanek P, Merkel S, Hohenberger W et al. Regional lymph node metastases and locoregional recurrence of rectal carcinoma in the era of optimized TME surgery. Implications for treatment decisions. Int J Colorect Dis 2009; 25: 359-68.
39. Daniels IR, Moran BJ, Heald RJ (2004) Surgery alone: is total mesorectal excision sufficient for rectal cancer? In: Controversies in gastrointestinal tumor therapy (eds. Wiegel T, Höcht S, Sternemann M et al. ), pp. 28-36. Karger, Basel.
40. Daniels IR, Strassburg J, Moran BJ. The need for future surgical low rectal cancer studies. Colorectal Dis 2006; 8(Suppl 3): 25-9.
41. Brown G, Richards CJ, Newcombe RG et al. Rectal carcinoma: thin-section MR imaging for staging in 28 patients. Radiology 1999; 211: 215-22.
42. Brown G, Radcliffe AG, Newcombe RG et al. Preoperative assessment of prognostic factors in rectal cancer using high resolution magnetic resonance imaging. Br J Surg 2003; 90: 355-64.
43. Lahaye MJ, Engelen SME, Nelemans PJ et al. Imaging for predicting the risk factors - the circumferential resection margins and nodal disease - of local recurrence in rectal cancer. A meta-analysis. Ultrasound CT MR 2005; 26: 259-68.
44. Hermanek P, Junginger T, Merkel S, Oberholzer K. High-resolution magnetic resonance imaging (MRI) in patients with rectal carcinoma. Effectiveness in selection for neoadjuvant treatment. Recent Res Devel Cancer 2006; 8: 39-56.
45. MERCURY Study Group. Diagnostic accuracy of preoperative magnetic resonance imaging in predicting curative resection of rectal cancer: prospective observational study. Br Med J 2006; 333: 779-84.
46. Engelen SME, Beets GL, Beets-Tan RGH. Role of preoperative local and distant staging in rectal cancer. Onkologie 2007; 30: 141-5.
47. Kornmann M, Henne-Bruns D. Qualität der Datengrundlage zu Evidence-based Medicine - Rektumkarzinom und präoperative 5x5 Bestrahlung. Zentralbl Chir 2008; 133: 20-4.
48. Quirke P, Steele R, Monson J et al. Effect of the plane of surgery achieved on local recurrence in patients with operable rectal cancer: a prospective study using data from the MRC CR07 and NCIC-CTG C016 randomised clinical trial. Lancet 2009; 373: 821-8.
49. Dent OF, Chapuis PH, Bokey EL, Newland RC. Methodology and reporting in studies of local recurrence after curative excision of the rectum for cancer. Br J Surg 2001; 88: 1476-80.
50. Wiggers T, van de Velde CJH. The circumferential margin in rectal cancer: recommendations based on the Dutch Total Mesorectal Excision Study. Eur J Cancer 2002; 38: 973-6.
51. Crawshaw A, Hennigan R, Smedley FH, Leslie MD. Perioperative radiotherapy for rectal cancer: the case for a selective pre-operative approach - the third way. Colorect Dis 2003; 5: 367-72.
52. Penninckx F, Danse E, on behalf of the PROCARE Workgroup. On the role of radiologists in the Belgian project on cancer of the rectum, PROCARE. JBR-BTR. J Belge Radiol 2006; 89: 19-22.
53. Rutten H, Sebag-Montefiore D, Glynne-Jones R et al. Capecitabine, oxaliplatin, radiotherapy, and excision (CORE) in patients with MRI-defined locally advanced rectal adenocarcinoma. Results of an international multicenter phase II study. J Clin Oncol 2006; 234: 18S abstract 3528.
54. Eriksen MT, Wibe A, Haffner J, Wiig JN, on behalf of the Norwegian Rectal Cancer Group. Prognostic groups in 1.676 patients with T3 rectal cancer treated without preoperative radiotherapy. Dis Colon Rectum 2007; 50: 156-67.
55. Pahlman L. (2008) Rectal cancer. In: European manual of medicine. Coloproctology (eds Herold A, Lehr P-A, Matzel KE, O'Connelll PR), pp. 213-8. Springer, Berlin, Heidelberg.New York.
56. Brown G, Daniels IR. Preoperative staging of rectal cancer: the MERCURY research project. Recent Results Cancer Res 2005; 165: 58-74.
57. Hermanek P. (1998) Qualität der Chirurgie aus der Sicht des Pathologen. In: Rektumkarzinom. Das Konzept der Totalen Mesorektalen Exzision (eds Büchler MW, Heald RJ, Maurer CA, Ulrich B), pp. 212-9. Karger, Basel.
58. Hermanek P. (2000) What can the pathologist tell the surgeon about rectal cancer resection? In: Colorectal cancer (ed Scholefield JH), pp. 80-90. Blackwell Science, Oxford.
59. Compton CC. Pathologic prognostic factors in the recurrence of rectal cancer. Clin Colorect Cancer 2002; 2: 149-160.
60. Nagtegaal ID, van de Velde CJH, van der Worp E et al. Macroscopic evaluation of rectal cancer resection specimen: clinical significance of the pathologist in quality control. J Clin Oncol 2002; 20: 1729-34.
61. Hermanek P, Hermanek P Jr, Hohenberger W et al. The pathological assessment of mesorectal excision - implications for further treatment and quality assessment. Int J Colorect Dis 2003; 18: 335-41.
62. Nagtegaal ID, van de Velde CJH, Marijnen CAM et al. Low rectal cancer: a call for a change of approach in abdominoperineal resection. J Clin Oncol 2005; 23: 9257-69.
63. Quirke P, Morris E. Reporting colorectal cancer. Histopathology 2007; 50: 103-12.
64. Maslekar S, Sharma A, MacDonald A et al. Mesorectal grades predict recurrences after curative resection for rectal cancer. Dis Colon Rectum 2006; 50: 168-75.
65. Jeyarajah S, Sutton CD, Miller AS, Hemingway D, on behalf of the Leicester Colorectal Specialist Group. Factors that influence the adequacy of total mesorectal excision for rectal cancer. Colorect Dis 2007; 9: 868-85.
66. Kube R, Ptok H, Wolff S et al. Quality of medical care in colorectal cancer in Germany. Onkologie 2009; 32: 25-9.
67. Ridwelski K, Lippert H, Gastinger I et al. Rektumkarzinomtherapie in Deutschland - Realität 2007. Abstract of lecture Gastrointestinal Oncology Update 2007, Wiesbaden.
68. Siegel R, Schlag PM, for the participants of the Berlin Rectal Carcinoma Study. TME-Qualitätsvergleich von laparoskopischer und offener Chirurgie im Rahmen der multizentrischen Berliner Rektumkarzinomstudie. Abstract of lecture Congress German Society of Surgery 2008, ID 9237.
69. Bittner R, Burghardt J, Gross E et al. (Arbeitsgruppe Workflow Rektumkarzinom II). Qualitätsindikatoren bei Diagnostik und Therapie des Rektumkarzinoms. Zentralbl Chir 2007; 132: 85-94.
70. Zirngibl H, Husemann B, Hermanek P. Intraoperative spillage of tumor cells in surgery for rectal cancer. Dis Colon Rectum 1990; 33: 610-14.
71. Hermanek P, Mansmann U, Altendorf-Hofmann A et al., für die Studiengruppe Kolorektales Karzinom (SGKRK). Vergleichende Beurteilung der onkologischen Ergebnisqualität beim colorectalen Carcinom. Klinikvergleiche anhand von Surrogatendpunkten?. Chirurg 1999; 70: 407-14.
72. Porter G, Soskolne C, Yakimets W et al. Surgeon-related factors and outcome in rectal cancer. Ann Surg 1998; 227: 157-67.
73. Eriksen MT, Wibe A, Syse A et al. Inadvertent perforation during rectal cancer resection in Norway. Br J Surg 2004; 91: 210-6.
74. Merkel S, Hohenberger W, Hermanek P. Intraoperative lokale Tumorzelldissemination in der Rektumkarzinomchirurgie. Chirurg 2010; 81: 719-27.
75. Maughan NJ, Quirke P. Modern management of colorectal cancer-a pathologist's view. Scand J Surg 2003; 92: 11-9.
76. Holm T, Ljung A, Häggmark T et al. Extended abdominoperineal resection with gluteus maximus flap reconstruction of the pelvic floor for rectal cancer. Br J Surg 2007; 94: 232-8.
77. Hermanek P. (2008) Current tumour classification. In: European manual of medicine. Coloproctology (eds Herold A, Lehur P-A, Matzel KE, O'Connell PR), pp. 225-34. Springer, Berlin, Heidelberg.
78. Jass JR, O'Brien MJ, Riddell RH, Snover DC. Recommendations for the reporting of surgically resected specimens of colorectal carcinoma. Virch Arch 2007; 450: 1-13.
79. Daugherty CK. (2005 7th edition) Ethical issues. In: Cancer. Principles & practice in oncolog (eds DeVita Jr VT, Hellmann S, Rosenberg SA), pp. 2747-58. Lippincott Williams & Wilkins, Philadelphia.
80. Ubel PA. (2006) Patient decision making. In: Oncology. An evidence-based approach (eds. Chang AE, Ganz PA, Hayes DF et al. ), pp. 177-83. Springer Science, New York.
81. Kornmann M, Porszolt F, Henne-Bruns D. Vergleichende Bewertung von Gesundheitsleistungen durch Laien am Beispiel der Therapie des Rektumkarzinoms. Zentralbl Chir 2008; 133: 148-55.
82. Bossema E, Stippelbout A, Baas-Thijssen M et al. Patient's preference for low rectal cancer surgery. Eur J Surg Oncol 2008; 34: 42-8.
83. Birgisson H, Pahlman L, Gunnarsson U, Glimelius B. Late gastrointestinal disorders after rectal cancer surgery with and without preoperative radiation therapy. Br J Surg 2008; 95: 206-13.
84. Lange MM, den Dulk M, Bossema ER et al. Risk factors for faecal incontinence after rectal cancer treatment. Br J Surg 2007; 94: 1278-84.
85. Peeters KCMJ, van de Velde CJH, Leer JWH et al. Late side effects of short-course preoperative radiotherapy combined with total mesorectal excision for rectal cancer: increased bowel dysfunction in irradiated patients - A Dutch Colorectal Cancer Group Study. J Clin Oncol 2005; 23: 6199-206.
86. Sauer R, Becker H, Hohenberger W et al. Preoperative versus postoperative chemoradiotherapy for rectal cancer. N Engl J Med 2004; 351: 1731-40.
87. Sebag-Montefiore D, Glynne-Jones R, Mortensen N et al. Pooled analysis of outcome measures including the histopathological R0 resection rate after pre-operative chemoradiation for locally advanced rectal cancer. In: Tripartite 2005 Colorectal Meeting (ed. Finan PJ). Blackwell Publishing, Dublin, Ireland.
88. Baik SH, Kim NK, Lee YC et al. Prognostic significance of circumferential resection margin following total mesorectal excision and adjuvant chemoradiotherapy in patients with rectal cancer. Ann Surg Oncol 2007; 14: 462-9.
89. Bakx R, Emons M, Legemate DA et al. Harm and benefits of short-term preoperative radiotherapy in patients with resectable rectal carcinomas. Eur J Surg Oncol 2006; 32: 520-36.